Deep Tech Startups

Arzeda designs proteins and metabolic pathways using computational tools, including its Archytas protein design software and Scylax metabolic pathway design software. The company operates in the computational biology and protein engineering field.

4 investors

Aspero Medical develops the Pillar balloon overtube solution with micro-textured design to improve control and anchoring during balloon endoscopy for small bowel diagnosis and treatment. The technology reduces procedure time and sedation requirements for gastrointestinal interventions.

4 investors

Addis Energy produces ammonia and other chemicals through a subsurface process that injects engineered fluids into iron-rich rock formations, leveraging geothermal and subsurface engineering techniques to reduce energy requirements by 85% compared to conventional Haber-Bosch processes. The company serves the chemical and fertilizer industries with a technology that decouples ammonia production from natural gas price volatility.

4 investors

Atalanta is a mathematical AI company that provides software verification and formal methods capabilities to ensure provably correct decision-making in complex systems for high-stakes missions in energy, space, and defense sectors.

4 investors

Atalanta is developing treatment options for intractable central nervous system diseases using RNA interference technology. The company was founded by leading experts in RNAi research.

4 investors

A wearable device company developing brain-sensing technology using nanotechnology for consumer use.

4 investors

fab2 designs and builds the hardware and software used to manufacture chips, including semiconductor fabs, fabrication tools, and components such as pumps, valves, sensors, and precision actuators. It also develops Studio, an in-browser collaborative EDA tool for chip design.

4 investors

Atomic Tessellator combines computational physics with machine learning and enterprise software architecture, though the page does not specify its product offering or customer market.

4 investors

Augmenta develops software that uses computational design and AI to automate building design, targeting the construction and engineering industry. The company applies its technology to problems in building design and construction technology.

4 investors

AutoNeura develops patent-protected control software that enables transient and real-world testing on absorbing dynamometers for powertrain development. The software reduces testing costs by over 50% while maintaining homologation-grade accuracy, serving automotive test facilities and powertrain engineers across automotive and marine sectors.

4 investors

Autopoiesis builds AI systems capable of autonomous scientific discovery, operating Aristotle, an AI research partner that assists scientists with hypothesis formation, evidence evaluation, and research direction decisions.

4 investors

Avenue Biosciences develops machine learning-enabled chemistry and software to accelerate the discovery and manufacturing of protein biologics for the biotechnology and therapeutics industry. The company combines high-throughput chemistry with computational tools to overcome production barriers in protein drug development.

4 investors

Averna Therapeutics is a biotechnology company developing therapeutics. The page is a team bio profiling its CEO and board member.

4 investors

AVES Reality converts real-world geographic data into simulation-ready 3D digital environments and HD maps for industrial applications. The company provides infrastructure for physical AI systems, enabling faster and more accurate 3D world reconstruction for autonomous systems training and testing.

4 investors

Axiomatic AI makes Lemma, an AI co-explorer for scientific and engineering work that helps users validate, derive, and analyze equations and reasoning across mathematics, physics, and engineering with reproducible Python-based modeling. It serves researchers and engineers, producing workspace artifacts such as Markdown notes, Python scripts, and Marimo notebooks.

4 investors

Axithra, a spin-off from Ghent University's Photonics Research Group and imec, develops an optics- and photonics-based platform for therapeutic drug monitoring that measures and monitors drug concentrations in blood at the point of care. Its lead application targets personalizing β-lactam antibiotic treatment for patients in intensive care units.

4 investors

Azora develops optical ground stations for space-to-Earth data communications. The company's systems enable satellites to transmit data at significantly higher speeds and lower cost than traditional radio frequency downlinks.

4 investors

BACTA is an AI-powered bioproduction company that uses microorganisms to produce industrial ingredients such as astaxanthin for cosmetics, human nutrition, and animal nutrition markets.

4 investors

Bacto.bio is a biotechnology company developing a multidisciplinary pipeline, staffed by scientists, engineers, and other technical specialists.

4 investors

A team of aerospace engineers and institutional investors that has invested in over 24 space economy companies, combining expertise in venture capital, capital markets, and space technology.

4 investors

Basilard BioTech develops Celletto, a nanomechanical (mechanoporation) gene delivery platform that inserts genes directly into the nucleus of cells without viral vectors, aimed at cell and gene therapy (CGT) developers and manufacturers. The technology targets the gene-delivery bottleneck in engineering cell-based therapies, offering an alternative to viral, chemical, and physical delivery methods.

4 investors

beeOLED develops blue OLED emitters based on rare-earth (lanthanide) metal complexes, such as cerium or europium, stabilized with organic ligands and made vacuum-vaporizable for OLED display manufacturing. It sells these emitter materials to OLED display and panel manufacturers, and operates its own synthesis laboratory and material pilot plant.

4 investors

BEIT provides physics-based computational approaches for drug discovery, embedding scientists with expertise in physics, mathematics, and engineering into pharmaceutical research programs.

4 investors

Beyond Barriers Therapeutics is a clinical-stage biotechnology company developing BBT-101, an intranasal therapeutic to reduce secondary effects from mild to moderate traumatic brain injuries. The company serves patients and medical professionals treating concussions, with support from the U.S. Department of Defense and NFLPA.

4 investors